Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.

BMC Cancer · 2006 · PMC1360086 · PMID 16417633

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

In fact in the presence of ZOL, the additional effect of docetaxel (~37% reduction in growth) was almost as great as that seen with ZOL compared with the control group (~42% reduction), although it should be noted that the comparison between ZOL and the ZOL/docetaxel combination failed to reach statistical significance because of modestly higher scatter within the ZOL-only group.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.